HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment: A randomised pilot study (KaMon study)

Hamid Hasson; Laura Galli; Giulia Gallotta; Valentina Neri; Pierluigi Blanc; Marco D'annunzio; Giulia Morsica; Salvatore Sollima; Marco Merli; Adriano Lazzarin; Caterina Uberti-Foppa

HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment: A randomised pilot study (KaMon study)

Hamid Hasson, Laura Galli, Giulia Gallotta, Valentina Neri, Pierluigi Blanc, Marco D'annunzio, Giulia Morsica, Salvatore Sollima, Marco Merli, Adriano Lazzarin, Caterina Uberti-Foppa

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

The aim of this randomised, prospective, open-label, multicentre pilot clinical trial was to compare the 48-week tox-icity profile of lopinavir/ritonavir (LPV/r) monotherapy with LPV/r-based HAART (KaMon = Kaletra monotherapy) in HIV/HCV patients undergoing HCV treatment. The study involved 30 HIV/HCV co-infected patients naïve to anti-HCV therapy. One patient in each arm (6.7%) discontinued anti-HCV therapy because of adverse events. There were no significant between-group differences in terms of the proportion of patients experiencing AEs (p=0.999) or the number of grade 3-4 AEs (p=0.146). No HIV failure was observed. The safety profile of LPV/r monotherapy was similar to that of LPV/r-based HAART, thus encouraging HAART simplification in patients receiving anti-HCV treatment.

Original language	English
Pages (from-to)	469-474
Number of pages	6
Journal	New Microbiologica
Volume	35
Issue number	4
Publication status	Published - 2012

Keywords

Anti-HCV drugs
HAART-simplification strategy
LPV/r monotherapy
Tolerability of HIV/HCV treatments

ASJC Scopus subject areas

Microbiology (medical)

Fingerprint Dive into the research topics of 'HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment: A randomised pilot study (KaMon study)'. Together they form a unique fingerprint.

Cite this

HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment : A randomised pilot study (KaMon study). / Hasson, Hamid; Galli, Laura; Gallotta, Giulia; Neri, Valentina; Blanc, Pierluigi; D'annunzio, Marco; Morsica, Giulia; Sollima, Salvatore; Merli, Marco; Lazzarin, Adriano; Uberti-Foppa, Caterina.

In: New Microbiologica, Vol. 35, No. 4, 2012, p. 469-474.

Research output: Contribution to journal › Article › peer-review

Hasson, Hamid ; Galli, Laura ; Gallotta, Giulia ; Neri, Valentina ; Blanc, Pierluigi ; D'annunzio, Marco ; Morsica, Giulia ; Sollima, Salvatore ; Merli, Marco ; Lazzarin, Adriano ; Uberti-Foppa, Caterina. / HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment : A randomised pilot study (KaMon study). In: New Microbiologica. 2012 ; Vol. 35, No. 4. pp. 469-474.

@article{ba1501e2c4004016b0543969cacacec3,

title = "HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment: A randomised pilot study (KaMon study)",

abstract = "The aim of this randomised, prospective, open-label, multicentre pilot clinical trial was to compare the 48-week tox-icity profile of lopinavir/ritonavir (LPV/r) monotherapy with LPV/r-based HAART (KaMon = Kaletra monotherapy) in HIV/HCV patients undergoing HCV treatment. The study involved 30 HIV/HCV co-infected patients na{\"i}ve to anti-HCV therapy. One patient in each arm (6.7%) discontinued anti-HCV therapy because of adverse events. There were no significant between-group differences in terms of the proportion of patients experiencing AEs (p=0.999) or the number of grade 3-4 AEs (p=0.146). No HIV failure was observed. The safety profile of LPV/r monotherapy was similar to that of LPV/r-based HAART, thus encouraging HAART simplification in patients receiving anti-HCV treatment.",

keywords = "Anti-HCV drugs, HAART-simplification strategy, LPV/r monotherapy, Tolerability of HIV/HCV treatments",

author = "Hamid Hasson and Laura Galli and Giulia Gallotta and Valentina Neri and Pierluigi Blanc and Marco D'annunzio and Giulia Morsica and Salvatore Sollima and Marco Merli and Adriano Lazzarin and Caterina Uberti-Foppa",

year = "2012",

language = "English",

volume = "35",

pages = "469--474",

journal = "New Microbiologica",

issn = "1121-7138",

publisher = "Luigi Ponzio e figlio Editori",

number = "4",

}

TY - JOUR

T1 - HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment

T2 - A randomised pilot study (KaMon study)

AU - Hasson, Hamid

AU - Galli, Laura

AU - Gallotta, Giulia

AU - Neri, Valentina

AU - Blanc, Pierluigi

AU - D'annunzio, Marco

AU - Morsica, Giulia

AU - Sollima, Salvatore

AU - Merli, Marco

AU - Lazzarin, Adriano

AU - Uberti-Foppa, Caterina

PY - 2012

Y1 - 2012

N2 - The aim of this randomised, prospective, open-label, multicentre pilot clinical trial was to compare the 48-week tox-icity profile of lopinavir/ritonavir (LPV/r) monotherapy with LPV/r-based HAART (KaMon = Kaletra monotherapy) in HIV/HCV patients undergoing HCV treatment. The study involved 30 HIV/HCV co-infected patients naïve to anti-HCV therapy. One patient in each arm (6.7%) discontinued anti-HCV therapy because of adverse events. There were no significant between-group differences in terms of the proportion of patients experiencing AEs (p=0.999) or the number of grade 3-4 AEs (p=0.146). No HIV failure was observed. The safety profile of LPV/r monotherapy was similar to that of LPV/r-based HAART, thus encouraging HAART simplification in patients receiving anti-HCV treatment.

AB - The aim of this randomised, prospective, open-label, multicentre pilot clinical trial was to compare the 48-week tox-icity profile of lopinavir/ritonavir (LPV/r) monotherapy with LPV/r-based HAART (KaMon = Kaletra monotherapy) in HIV/HCV patients undergoing HCV treatment. The study involved 30 HIV/HCV co-infected patients naïve to anti-HCV therapy. One patient in each arm (6.7%) discontinued anti-HCV therapy because of adverse events. There were no significant between-group differences in terms of the proportion of patients experiencing AEs (p=0.999) or the number of grade 3-4 AEs (p=0.146). No HIV failure was observed. The safety profile of LPV/r monotherapy was similar to that of LPV/r-based HAART, thus encouraging HAART simplification in patients receiving anti-HCV treatment.

KW - Anti-HCV drugs

KW - HAART-simplification strategy

KW - LPV/r monotherapy

KW - Tolerability of HIV/HCV treatments

UR - http://www.scopus.com/inward/record.url?scp=84869184772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869184772&partnerID=8YFLogxK

M3 - Article

C2 - 23109014

AN - SCOPUS:84869184772

VL - 35

SP - 469

EP - 474

JO - New Microbiologica

JF - New Microbiologica

SN - 1121-7138

IS - 4

ER -